Gensaic

Gensaic is developing a novel gene therapy delivery modality that can be applied for multiple diseases. M13 bacteriophages are viruses that reside within the human gut that infect bacterial cells. Gensaic is re-engineering these phages to target specific tissues within the body and overcome the capacity, immunogenicity and manufacturing difficulties associated with other delivery forms available. Gensaic has received funding from the Cystic Fibrosis Foundation to design their delivery modality toward lung tissue.

Jobs: